Immune-based Therapies
Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single-Center Retrospective Study
Oncology 2025 January 24 [Link] Tomoki Higashiyama, Kozo Kuribayashi, Hiroshi Doi, Aki Kubota, Taiichiro Otsuki, Yasuhiro Nakajima, Koji Mikami, Ryo Takahashi, Akifumi Nakamura, Daichi Fujimoto, Kazuhiro Kitajima, Toshiyuki Minami, Takashi Kijima Abstract Introduction: In August 2018, the Japanese PMDA approved nivolumab, an immune checkpoint inhibitor, for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (PM)…
Read MoreEcteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma
Journal of Experimental & Clinical Cancer Research 2024 December 21 [Link] I C Salaroglio, P Aviles, J Kopecka, A Merlini, F Napoli, L Righi, S Novello, H Sullivan, C Cuevas, G V Scagliotti, C Riganti Abstract Background: Malignant pleural mesothelioma (MPM) is a highly chemo-refractory and immune-evasive tumor that presents a median overall survival of…
Read MoreSerum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
Frontiers in Immunology 2024 December 2 [Link] Saima Jamil Farooqi, Zhi Zhao, Åsa Kristina Öjlert, Solfrid Thunold, Hedvig Vidarsdotter Juul, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Hanne Marte Gjertsen Nymoen, Åslaug Helland, Vilde Drageset Haakensen Abstract Background: Pleural mesothelioma (PM) is a rare cancer with a dismal prognosis. Dual immune checkpoint inhibitors have improved overall survival,…
Read MoreAffinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity
JCI Insight 2024 November 22 [Link] Yanping Yang, Yogindra Vedvyas, Yago Alcaina, Sydney J Trumper, Diella S Babu, Irene M Min, Jacqueline M Tremblay, Charles B Shoemaker, Moonsoo M Jin Abstract The application of chimeric antigen receptor (CAR) T cell therapy in solid tumors is hindered by life-threatening toxicities resulting from on-target, off-tumor killing of…
Read MoreEfficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study
Genome Medicine 2024 November 15 [Link] Tongpeng Xu, Tian Tian, Chen Wang, Xiaofeng Chen, Xiangrong Zuo, Hanyu Zhou, Jianan Bai, Chenhui Zhao, Sujie Fu, Chongqi Sun, Ting Wang, Ling Zhu, Jingzhi Zhang, Enxiu Wang, Ming Sun, Yongqian Shu Abstract Background: Despite remarkable achievements in applying chimeric antigen receptor (CAR)-T cells to treat hematological malignancies, they…
Read MoreEpithelioid pleural mesothelioma successfully treated with perioperative immunotherapy: a case report
General Thoracic Cardiovascular Surgical Cases 2024 June 11 [Link] Gaku Yamazaki, Aki Fujiwara-Kuroda, Jun Muto, Hideki Ujiie, Masato Aragaki, Megumi Furuta, Sakurako Ohno, Kanako C Hatanaka, Yutaka Hatanaka, Yoshihiro Matsuno, Tatsuya Kato Abstract Background: Pleural mesothelioma, characterized by a dismal prognosis even with multimodal therapy, has seen emerging interest in immune checkpoint inhibitors (ICIs) due…
Read MoreSafety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
BMC Cancer 2024 November 5 [Link] Amjad Zafar, Asma Abdul Rashid, Abdul Moeed, Muhammad Junaid Tahir, Ahmad Jamal Khan, Oadi N Shrateh, Ali Ahmed Abstract Background: Malignant mesothelioma is an aggressive cancer with poor prognosis. Programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) have recently presented as a viable…
Read MoreReal-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study
Asia-Pacific Journal of Clinical Oncology 2024 December [Link] Kar Ven Cavan Chow, Cassie Turner, Brett Hughes, Zarnie Lwin, Bryan Chan Abstract Aim: To evaluate the real-world treatment patterns and outcomes for patients with pleural mesothelioma (PM) in the era of immunotherapy. Methods: This retrospective audit included patients with PM diagnosed within three tertiary referral centers…
Read MoreAntigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma
Scientific Reports 2024 October 29 [Link] Kim Lindland, Marion Masitsa Malenge, Ruth Gong Li, Roxanne Wouters, Tina Bjørnlund Bønsdorff, Asta Juzeniene, Srdan M Dragovic Abstract Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of…
Read MoreMesothelioma survival prediction based on a six-gene transcriptomic signature
iScience 2024 September 23 [Link] Kiarash Behrouzfar, Steve E Mutsaers, Wee Loong Chin, Kimberley Patrick, Isaac Trinstern Ng, Fiona J Pixley, Grant Morahan, Richard A Lake, Scott A Fisher Abstract Mesothelioma is a lethal cancer. Despite promising outcomes associated with immunotherapy, durable responses remain restricted to a minority of patients, highlighting the need for improved…
Read More